Correction to: Regional [¹⁸F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease

Correction to: Eur J Nucl Med Mol Imaging

10.1007/s00259-020-04758-2

The authors regret to inform readers that the following error was detected in the original article. The values for entorhinal, limbic and neortical SUVr were switched between SCD Aβ + and Aβ- in Table 1 and have now been corrected. Unnecessary symbols in Table 2 have been removed.

Table 1.

Demographic, clinical and AD biomarker characteristics over the total sample and per disease group

	SCD Aβ+ (n = 10)	SCD Aβ- (n = 15)	MCI/AD (n = 53)	Total Sample (n = 78)	Total SCD (n = 25)
Age, years	67 ± 6	64 ± 6	65 ± 7	65 ± 7	65 ± 6
Female, %	60%	60%	53%	43%	60%
No. Aß positive subjects	10(100%)	0(0%)	53 (100%)	63 (81%)	10 (40%)
Education, Verhage scale, median(range)	6 (4–7)	6 (2–7)	6 (3–7)	6 (2–7)	6 (2–7)
Time lag LP/PET, years	0.7 ± 0.6	0.9 ± 0.5	0.6 ± 0.5	0.7 ± 0.5	0.8 ± 0.7
Neuropsychological measures
MMSE (n = 78)	28 ± 1	28 ± 1	23 ± 4b	25 ± 4	28 ± 1
Memoryc (n = 78)	−0.5 ± 0.8	0.3 ± 0.6	−3.1 ± 2.1b	−2.1 ± 2.3	−0.0 ± 0.8
Attentiond (n = 73)	−0.2 ± 0.6	0.1 ± 0.6	−1.3 ± 1.2b	−0.9 ± 1.2	−0.0 ± 0.6
Languagee (n = 68)	−0.0 ± 0.4	0.0 ± 0.8	−1.0 ± 1.0b	−0.6 ± 1.0	−0.0 ± 0.7
Executive functioningf (n = 73)	−0.1 ± 0.9	−0.1 ± 0.7	−2.4 ± 1.0b	−0.9 ± 1.1	0.0 ± 0.8
Tau biomarkers
CSF
CSF Aß1–42	779 ± 197	1067 ± 217	541 ± 113b	677 ± 260	966 ± 247
CSF t-tau	615 ± 383	257 ± 201	760 ± 412b	645 ± 422	401 ± 333
CSF p-tau	83 ± 36	43 ± 23	90 ± 35b	80 ± 38	59 ± 38
[18F]flortaucipir PET
Entorhinal cortex BPND	0.2 ± 0.2	−0.1 ± 0.1	0.3 ± 0.2b	0.2 ± 0.2	−0.0 ± 0.2
Limbic region BPND	0.2 ± 0.1	0.0 ± 0.0	0.4 ± 0.2b	0.3 ± 0.2	0.1 ± 0.1
Neocortex BPND	0.1 ± 0.1	−0.0 ± 0.0	0.3 ± 0.3b	0.2 ± 0.3	0.0 ± 0.1
Entorhinal cortex SUVr	1.3 ± 0.2	1.0 ± 0.1	1.5 ± 0.2b	1.4 ± 0.3	1.1 ± 0.2
Limbic region SUVr	1.3 ± 0.2	1.1 ± 0.1	1.5 ± 0.2b	1.4 ± 0.3	1.2 ± 0.1
Neocortex SUVr	1.2 ± 0.2	1.1 ± 0.1	1.4 ± 0.3b	1.3 ± 0.3	1.1 ± 0.1

Continuous data shown as mean ± standard deviation, unless specified otherwise. Differences in demographic, clinical and AD biomarker characteristics between disease groups were assessed using ANOVA for continuous variables and χ ² for dichotomous data. ^a Significantly different from SCD subjects at p < 0.05. ^b Significantly different from SCD subjects at p < 0.01 ^c-Z-score Memory domain, ^dZ-score Attention domain, ^eZ-score Language domain, ^f Z-score Executive functioning domain

Table 2.

Standardized ß coefficients for the relationship between CSF p-tau and entorhinal, limbic and neocortical [¹⁸F]flortaucipir BP_ND or SUVr over the total sample and stratified per disease group

	Total Sample (n = 78)	SCD (n = 25)	MCI/AD (n = 53)
	CSF p-tau	CSF p-tau	CSF p-tau
Entorhinal[18F]flortaucipir BPND	0.46(p < 0.01)	0.43(p = 0.07)	0.17(p = 0.17)
Limbic [18F]flortaucipir BPND	0.45(p < 0.01)	0.59(p = 0.01)	0.22(p = 0.08)
Neocortical [18F]flortaucipir BPND	0.43(p < 0.01)	0.54(p = 0.02)	0.27(p = 0.03)
Entorhinal[18F]flortaucipir SUVr	0.50(p < 0.01))	0.59(p < 0.01)	0.16(p = 0.21)
Limbic [18F]flortaucipir SUVr	0.47(p < 0.01)	0.67(p < 0.01)	0.21(p = 0.09)
Neocortical [18F]flortaucipir SUVr	0.43(p < 0.01)	0.41(p = 0.08)	0.26(p = 0.03)

Standardized ß coefficients (significant in bold) from regression analysis with [¹⁸F]flortaucipir BP_ND or SUVr as the dependent variables and CSF p-tau as predictor

Effects adjusted for age, sex and time lag between LP and [¹⁸F]flortaucipir PET